• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GNS Healthcare, Covance to enable more efficient, cost-effective drug development

GNS Healthcare, Covance to enable more efficient, cost-effective drug development

September 21, 2012
CenterWatch Staff

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

Combining GNS's supercomputer-driven REFS (Reverse Engineering and Forward Simulation) big data analytics platform and Covance's data assets derived from its extensive clinical and scientific support of pharmaceutical drug development, the companies will create computer models that predict the likelihood of development success for a drug candidate given available safety and efficacy data across a variety of patient characteristics, across many diseases, starting with type 2 diabetes. Financial terms of the agreement were not disclosed.

"Our collaboration with Covance combines our unique collective resources and capabilities to tackle what has previously been an intractable challenge—improving dismal clinical drug development success rates," said Colin Hill, president, CEO and co-founder of GNS Healthcare. "The predictive computer models arising from our collaboration will address this problem and will in turn lead to better treatment options for patients.”

The collaboration complements GNS' existing work with several major pharmaceutical companies in creating treatment algorithms to match patients to drugs and to discover novel biomarkers from wide-ranging molecular and clinical trial data.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing